Andrew Cheng, President and CEO at Akero Therapeutics, Inc. (AKRO), sold 46,411 shares at $53.67 ($2.5M) on 2025-02-10, disclosed to the SEC on 2025-02-11.
Scheduled sale ($2.5M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $51.75 | 12,640 | $654K | 26.6% |
| 2 | $52.91 | 6,439 | $341K | 13.9% |
| 3 | $52.91 | 6,439 | $341K | 13.9% |
| 4 | $53.67 | 9,972 | $535K | 21.8% |
| 5 | $53.67 | 9,972 | $535K | 21.8% |
| 6 | $54.55 | 749 |
| $41K |
| 1.7% |
| 7 | $55.81 | 200 | $11K | 0.5% |
| Total | $52.96 avg | 46,411 | $2.5M | 100% |
| Filing → |
| AKRO | SELL | 2025-08-13 | $2.9M | — | Filing → |
| AKRO | SELL | 2025-07-11 | $3.1M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $726K | — | Filing → |